Similar articles for PMID: 28848035

Year	Number of Results
1988	1
1993	2
1994	1
1995	1
1996	2
1997	1
1998	2
1999	2
2000	1
2001	1
2002	3
2003	10
2004	6
2005	5
2006	2
2007	3
2008	5
2009	6
2010	1
2011	2
2012	6
2013	5
2014	3
2015	11
2016	9
2017	11
2018	15
2019	9
2020	15
2021	21
2022	9
2023	2
2024	0

1

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan.

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C. Blakkisrud J, et al. J Nucl Med. 2018 Apr;59(4):704-710. doi: 10.2967/jnumed.117.195347. Epub 2017 Aug 28. J Nucl Med. 2018. PMID: 28848035 Free article. Clinical Trial.

2

Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. Stokke C, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22. Eur J Nucl Med Mol Imaging. 2018. PMID: 29470615 Free PMC article. Clinical Trial.

3

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C. Blakkisrud J, et al. J Nucl Med. 2017 Jan;58(1):55-61. doi: 10.2967/jnumed.116.180471. Epub 2016 Sep 1. J Nucl Med. 2017. PMID: 27587710 Free article.

4

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C. Blakkisrud J, et al. J Nucl Med. 2017 Jan;58(1):48-54. doi: 10.2967/jnumed.116.173922. Epub 2016 Aug 4. J Nucl Med. 2017. PMID: 27493270 Free article.

5

FDG PET/CT and Dosimetric Studies of ¹⁷⁷Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?

Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C. Løndalen A, et al. Mol Imaging Biol. 2022 Oct;24(5):807-817. doi: 10.1007/s11307-022-01731-3. Epub 2022 Apr 29. Mol Imaging Biol. 2022. PMID: 35486292 Free PMC article. Clinical Trial.

6

¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.

Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV. Malenge MM, et al. J Nucl Med. 2020 Oct;61(10):1468-1475. doi: 10.2967/jnumed.119.237230. Epub 2020 Apr 3. J Nucl Med. 2020. PMID: 32245896 Free PMC article.

7

Myelosuppression in patients treated with ¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.

Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C. Blakkisrud J, et al. Acta Oncol. 2021 Nov;60(11):1481-1488. doi: 10.1080/0284186X.2021.1959635. Epub 2021 Aug 23. Acta Oncol. 2021. PMID: 34425735

8

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.

Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C. Løndalen A, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1902-1914. doi: 10.1007/s00259-020-05098-x. Epub 2020 Nov 16. Eur J Nucl Med Mol Imaging. 2021. PMID: 33196921 Free PMC article. Clinical Trial.

9

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Kolstad A, et al. Blood Adv. 2020 Sep 8;4(17):4091-4101. doi: 10.1182/bloodadvances.2020002583. Blood Adv. 2020. PMID: 32877524 Free PMC article. Clinical Trial.

10

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

148 results

Results by year